Anyhow, the insensitivity of V2R-R137L/C mutants to vaptans, differently to V2R-F229V and V2R-I130N variants that are sensitive to vaptans [2,10,12,13,36], suggests that Gα12/13–RhoA–ROCK signaling pathway may be potential therapeutic targets for NSIAD in patients carrying these mutations. The gene discussed is RHOA; the disease is nephrogenic syndrome of inappropriate antidiuresis.